Pasar al contenido principal

LA RUTA ANEMIA DE FANCONI/BRCA: INVESTIGACION GENETICA Y TERAPEUTICA

RTI2018-098419-B-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario INSTITUT DE RECERCA DE L HOSPITAL DE LA SANTA CREU I SANT PAU

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

CDK5RAP3, a New BRCA2 Partner That Regulates DNA Repair, Is Associated with Breast Cancer Survival

  • Minguillón, Jordi
  • Ramírez, María José
  • Rovirosa, Llorenç
  • Bustamante-Madrid, Pilar
  • Camps-Fajol, Cristina
  • Ruiz de Garibay, Gorka
  • Shimelis, Hermela
  • Montanuy, Helena
  • Pujol, Roser
  • Hernandez, Gonzalo
  • Bogliolo, Massimo
  • Castillo, Pau
  • Soucy, Penny
  • Martrat, Griselda
  • Sánchez Gómez, Antonio Higinio
  • Cuadras, Daniel
  • García, María J.
  • Gayarre, Javier
  • Lázaro, Conxi
  • Benítez, Javier
  • Couch, Fergus J.
  • Pujana, Miquel Angel
  • Surrallés, Jordi
BRCA2 is essential for homologous recombination DNA repair. BRCA2 mutations lead to genome instability and increased risk of breast and ovarian cancer. Similarly, mutations in BRCA2-interacting proteins are also known to modulate sensitivity to DNA damage agents and are established cancer risk factors. Here we identify the tumor suppressor CDK5RAP3 as a novel BRCA2 helical domain-interacting protein. CDK5RAP3 depletion induced DNA damage resistance, homologous recombination and single-strand annealing upregulation, and reduced spontaneous and DNA damage-induced genomic instability, suggesting that CDK5RAP3 negatively regulates double-strand break repair in the S-phase. Consistent with this cellular phenotype, analysis of transcriptomic data revealed an association between low CDK5RAP3 tumor expression and poor survival of breast cancer patients. Finally, we identified common genetic variations in the CDK5RAP3 locus as potentially associated with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Our results uncover CDK5RAP3 as a critical player in DNA repair and breast cancer outcomes., Surrallés laboratory is supported by the ICREA Academia programme, Spanish Ministry of Science, Innovation and Universities (projects CB06/07/0023 MCI, UE and RTI2018-098419-B-I00 MCI/AEI/FEDER, UE), European Commission (and P-SPHERE COFUND project), Fanconi Anemia Research Fund Inc. This work was also funded by intramural actions (ACCI-U705/U745-2018 to JS) of CIBERER. CIBERER is an initiative of the Instituto de Salud Carlos III, Spain. M.A.P. laboratory was funded by the Instituto de Salud Carlos III grants PI18/01029 and PI21/01306, Generalitat de Catalunya SGR 2017-449, and CERCA Program to IDIBELL. The CIMBA data management and data analysis were supported by Cancer Research UK grants C12292/A20861 and PPRPGM-Nov20\100002. iCOGS: the European Community’s Seventh Framework Programme under grant agreement n 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112–the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer (CRN-87521), and the Ministry of Economic Development, Innovation and Export Trade (PSR-SIIRI-701), Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund. The PERSPECTIVE project was supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the Ministry of Economy, Science and Innovation through Genome Québec, and The Quebec Breast Cancer Foundation., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

  • Figlioli, Gisella
  • Catucci, Irene
  • Caleca, Laura
  • Lasheras, Sandra Viz
  • Pujol, Roser
  • Balmaña Gelpí, Judith
  • Diez Gibert, Orland
  • Bogliolo, Massimo
Càncer de mama; Genètica del càncer, Cáncer de mama; Genética del cáncer, Breast cancer; Cancer genetics, Breast cancer is a common disease partially caused by genetic risk factors. Germline pathogenic variants in DNA repair genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 are associated with breast cancer risk. FANCM, which encodes for a DNA translocase, has been proposed as a breast cancer predisposition gene, with greater effects for the ER-negative and triple-negative breast cancer (TNBC) subtypes. We tested the three recurrent protein-truncating variants FANCM:p.Arg658*, p.Gln1701*, and p.Arg1931* for association with breast cancer risk in 67,112 cases, 53,766 controls, and 26,662 carriers of pathogenic variants of BRCA1 or BRCA2. These three variants were also studied functionally by measuring survival and chromosome fragility in FANCM -/- patient-derived immortalized fibroblasts treated with diepoxybutane or olaparib. We observed that FANCM:p.Arg658* was associated with increased risk of ER-negative disease and TNBC (OR = 2.44, P = 0.034 and OR = 3.79; P = 0.009, respectively). In a country-restricted analysis, we confirmed the associations detected for FANCM:p.Arg658* and found that also FANCM:p.Arg1931* was associated with ER-negative breast cancer risk (OR = 1.96; P = 0.006). The functional results indicated that all three variants were deleterious affecting cell survival and chromosome stability with FANCM:p.Arg658* causing more severe phenotypes. In conclusion, we confirmed that the two rare FANCM deleterious variants p.Arg658* and p.Arg1931* are risk factors for ER-negative and TNBC subtypes. Overall our data suggest that the effect of truncating variants on breast cancer risk may depend on their position in the gene. Cell sensitivity to olaparib exposure, identifies a possible therapeutic option to treat FANCM-associated tumors., Peterlongo laboratory is supported by Associazione Italiana Ricerca sul Cancro (AIRC; IG2015 no.16732) to P. Peterlongo and by a fellowship from Fondazione Umberto Veronesi to G. Figlioli. Surrallés laboratory is supported by the ICREA-Academia program, the Spanish Ministry of Health (projects FANCOSTEM and FANCOLEN), the Spanish Ministry of Economy and Competiveness (projects CB06/07/0023 and RTI2018-098419-B-I00), the European Commission (EUROFANCOLEN project HEALTH-F5-2012-305421 and P-SPHERE COFUND project), the Fanconi Anemia Research Fund Inc, and the “Fondo Europeo de Desarrollo Regional, una manera de hacer Europa” (FEDER). CIBERER is an initiative of the Instituto de Salud Carlos III, Spain.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The FANCM :p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

  • Figlioli, Gisella|||0000-0002-0740-1363
  • Bogliolo, Massimo|||0000-0001-8240-7784
  • Catucci, Irene
  • Caleca, Laura|||0000-0002-3381-7493
  • Viz Lasheras, Sandra|||0000-0001-5873-5104
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Kiiski, Johanna I.
  • Muranen, Taru A.|||0000-0002-5895-1808
  • Barnes, Daniel R.|||0000-0002-3781-7570
  • Dennis, Joe|||0000-0003-4591-1214
  • Michailidou, Kyriaki
  • Bolla, Manjeet K.|||0000-0002-4351-9326
  • Leslie, Goska|||0000-0001-5756-6222
  • Aalfs, Cora M.
  • Adank, Muriel A.
  • Adlard, Julian|||0000-0002-1693-0435
  • Agata, Simona
  • Cadoo, Karen
  • Agnarsson, Bjarni A.
  • Ahearn, Thomas
  • Aittomäki, Kristiina
  • Ambrosone, Christine B.
  • Andrews, Lesley
  • Anton-Culver, Hoda
  • Antonenkova, Natalia N.
  • Arndt, Volker|||0000-0001-9320-8684
  • Arnold, Norbert
  • Aronson, Kristan J.
  • Arun, Banu K.
  • Asseryanis, Ella
  • Auber, Bernd|||0000-0003-1880-291X
  • Auvinen, Päivi
  • Azzollini, Jacopo
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Barkardottir, Rosa B.
  • Barrowdale, Daniel|||0000-0003-1661-3939
  • Barwell, Julian
  • Beane-Freeman, Laura
  • Beauparlant, Charles Joly
  • Beckmann, Matthias W.
  • Behrens, Sabine
  • Benitez, Javier|||0000-0002-0923-7202
  • Berger, Raanan
  • Bermisheva, Marina
  • Blanco, Amie M.
  • Blomqvist, Carl
  • Bogdanova, Natalia V.
  • Bojesen, Anders|||0000-0003-4289-8595
  • Bojesen, Stig E.
  • Bonanni, Bernardo|||0000-0003-3589-2128
  • Borg, Åke
  • Brady, Angela F.
  • Brauch, Hiltrud|||0000-0001-7531-2736
  • Brenner, Hermann
  • Brüning, Thomas
  • Burwinkel, Barbara
  • Buys, Saundra|||0000-0003-4120-5697
  • Caldes, Trinidad
  • Caliebe, Almuth
  • Caligo, Maria|||0000-0003-0589-1829
  • Campa, Daniele|||0000-0003-3220-9944
  • Campbell, Ian|||0000-0002-7773-4155
  • Canzian, Federico|||0000-0002-4261-4583
  • Castelao, Jose E.
  • Chang-Claude, Jenny
  • Chanock, Stephen|||0000-0002-2324-3393
  • Claes, Kathleen|||0000-0003-0841-7372
  • Clarke, Christine L.
  • Collavoli, Anita
  • Conner, Thomas A.
  • Cox, David G.
  • Cybulski, Cezary|||0000-0002-2819-3057
  • Czene, Kamila
  • Daly, Mary B.
  • Hoya, Miguel de la|||0000-0002-8113-1410
  • Devilee, Peter|||0000-0002-8023-2009
  • Diez, Orland|||0000-0001-7339-0570
  • Ding, Yuan Chun
  • Dite, Gillian S.
  • Ditsch, Nina
  • Domchek, Susan M.|||0000-0002-5914-7272
  • Dorfling, Cecilia M.
  • dos-Santos-Silva, Isabel
  • Durda, Katarzyna
  • Dwek, Miriam
  • Eccles, Diana M.|||0000-0002-9935-3169
  • Ekici, Arif B.
  • Eliassen, A. Heather
  • Ellberg, Carolina
  • Eriksson, Mikael
  • Evans, Gareth|||0000-0002-8482-5784
  • Fasching, Peter A.
  • Figueroa, Jonine
  • Flyger, Henrik
  • Foulkes, William|||0000-0001-7427-4651
  • Friebel, Tara M.
  • Friedman, Eitan|||0000-0002-6745-1733
  • Gabrielson, Marike
  • Gaddam, Pragna
  • Gago-Dominguez, Manuela
  • Gao, Chi
  • Gapstur, Susan M.
  • Garber, Judy
  • García-Closas, Montserrat
  • García-Sáenz, José A.|||0000-0001-6880-0301
  • Gaudet, Mia M.
  • Gayther, Simon A.|||0000-0001-7937-5443
  • Giles, Graham G.
  • Glendon, Gord
  • Godwin, Andrew K.|||0000-0002-3987-9580
  • Goldberg, Mark S.
  • Goldgar, David E.
  • Guénel, Pascal
  • Gutierrez-Barrera, Angelica M.
  • Haeberle, Lothar
  • Haiman, Christopher A.
  • Håkansson, Niclas
  • Hall, Per
  • Hamann, Ute|||0000-0001-6705-7624
  • Harrington, Patricia A.
  • Hein, Alexander
  • Heyworth, Jane
  • Hillemanns, Peter
  • Hollestelle, Antoinette
  • Hopper, John L.
  • Hosgood, H. Dean
  • Howell, Anthony
  • Hu, Chunling
  • Hulick, Peter J.
  • Hunter, David J.
  • Imyanitov, Evgeny N.
  • Isaacs, Claudine|||0000-0002-9646-1260
  • Jakimovska, Milena|||0000-0002-1506-0669
  • Jakubowska, Anna|||0000-0002-5650-0501
  • James, Paul|||0000-0002-4361-4657
  • Janavicius, Ramunas
  • Janni, Wolfgang
  • John, Esther M.
  • Jones, Michael E.
  • Jung, Audrey
  • Kaaks, Rudolf
  • Karlan, Beth Y.|||0000-0002-9451-2933
  • Khusnutdinova, Elza
  • Kitahara, Cari M.
  • Konstantopoulou, Irene|||0000-0002-0470-0309
  • Koutros, Stella
  • Kraft, Peter
  • Lambrechts, Diether
  • Lázaro García, Conxi|||0000-0002-7198-5906
  • Le Marchand, Loic
  • Lester, Jenny
  • Lesueur, Fabienne|||0000-0001-7404-4549
  • Lilyquist, Jenna
  • Loud, Jennifer T.
  • Lu, Karen H.
  • Luben, Robert N.
  • Lubinski, Jan|||0000-0003-2931-3003
  • Mannermaa, Arto
  • Manoochehri, Mehdi
  • Manoukian, Siranoush
  • Margolin, Sara
  • Martens, John W. M.
  • Maurer, Tabea
  • Mavroudis, Dimitrios
  • Mebirouk, Noura
  • Meindl, Alfons
  • Menon, Usha|||0000-0003-3708-1732
  • Miller, Austin|||0000-0001-9739-8462
  • Montagna, Marco
  • Nathanson, Katherine L.|||0000-0002-6740-0901
  • Neuhausen, Susan L.|||0000-0001-5053-0390
  • Newman, William G.
  • Nguyen-Dumont, Tu
  • Nielsen, Finn Cilius
  • Nielsen, Sarah
  • Nikitina-Zake, Liene
  • Offit, Kenneth
  • Olah, Edith
  • Olopade, Olufunmilayo I.|||0000-0002-9936-1599
  • Olshan, Andrew F.
  • Olson, Janet E.
  • Olsson, Håkan
  • Osorio, Ana|||0000-0001-8124-3984
  • Ottini, Laura
  • Peissel, Bernard|||0000-0001-9233-3571
  • Peixoto, Ana
  • Peto, Julian|||0000-0002-1685-8912
  • Plaseska-Karanfilska, Dijana
  • Pocza, Timea
  • Presneau, Nadege
  • Pujana, Miguel Angel|||0000-0003-3222-4044
  • Punie, Kevin|||0000-0002-1162-7963
  • Rack, Brigitte
  • Rantala, Johanna
  • Rashid, Muhammad U.|||0000-0002-7684-3122
  • Rau-Murthy, Rohini
  • Rennert, Gad|||0000-0002-8512-068X
  • Lejbkowicz, Flavio|||0000-0001-5718-0418
  • Rhenius, Valerie
  • Romero, Atocha|||0000-0002-1634-7397
  • Rookus, Matti A.
  • Ross, Eric A.
  • Rossing, Maria
  • Rudaitis, Vilius
  • Ruebner, Matthias
  • Saloustros, Emmanouil|||0000-0002-0485-0120
  • Sanden, Kristin
  • Santamariña, Marta
  • Scheuner, Maren T.
  • Schmutzler, Rita K.
  • Schneider, Michael
  • Scott, Christopher|||0000-0003-1340-0647
  • Senter, Leigha
  • Shah, Mitul
  • Sharma, Priyanka
  • Shu, Xiao-Ou
  • Simard, Jacques|||0000-0001-6906-3390
  • Singer, Christian F.
  • Sohn, Christof
  • Soucy, Penny
  • Southey, Melissa C.|||0000-0002-6313-9005
  • Spinelli, John J.
  • Steele, Linda
  • Stoppa-Lyonnet, Dominique
  • Tapper, William J.
  • Teixeira, Manuel R.|||0000-0002-4896-5982
  • Terry, Mary Beth
  • Thomassen, Mads
  • Thompson, Jennifer
  • Thull, Darcy L.
  • Tischkowitz, Marc
  • Tollenaar, Rob A. E. M.
  • Torres, Diana
  • Troester, Melissa A.
  • Truong, Thérèse
  • Tung, Nadine
  • Untch, Michael
  • Vachon, Celine M.
  • van Rensburg, Elizabeth J.|||0000-0003-2077-230X
  • van Veen, Elke M.
  • Vega, Ana|||0000-0002-7416-5137
  • Viel, Alessandra|||0000-0003-2804-0840
  • Wappenschmidt, Barbara
  • Weitzel, Jeffrey N.
  • Wendt, Camilla
  • Wieme, Greet|||0000-0003-2718-5300
  • Wolk, Alicja
  • Yang, Xiaohong R.
  • Zheng, Wei|||0000-0003-1226-070X
  • Ziogas, Argyrios|||0000-0003-4529-3727
  • Zorn, Kristin K.
  • Dunning, Alison M.
  • Lush, Michael
  • Wang, Qin
  • McGuffog, Lesley|||0000-0003-1237-0546
  • Parsons, Michael T.
  • Pharoah, Paul D.P.|||0000-0001-8494-732X
  • Fostira, Florentia
  • Toland, Amanda Ewart|||0000-0002-0271-1792
  • Andrulis, Irene L.|||0000-0002-4226-6435
  • Ramus, Susan J.|||0000-0003-0005-7798
  • Swerdlow, Anthony J.
  • Greene, Mark H.|||0000-0003-1852-9239
  • Chung, Wendy
  • Milne, Roger L.|||0000-0001-5764-7268
  • Chenevix-Trench, Georgia
  • Dörk, Thilo|||0000-0002-9458-0282
  • Schmidt, Marjanka K.|||0000-0002-2228-429X
  • Easton, Douglas F.|||0000-0003-2444-3247
  • Radice, Paolo|||0000-0001-6298-4111
  • Hahnen, Eric|||0000-0002-1152-8367
  • Antoniou, Antonis C.
  • Couch, Fergus J.
  • Nevanlinna, Heli|||0000-0002-0916-2976
  • Surralles, Jordi|||0000-0002-4041-7519
  • Peterlongo, Paolo|||0000-0001-6951-6855
Breast cancer is a common disease partially caused by genetic risk factors. Germline pathogenic variants in DNA repair genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 are associated with breast cancer risk. FANCM, which encodes for a DNA translocase, has been proposed as a breast cancer predisposition gene, with greater effects for the ER-negative and triple-negative breast cancer (TNBC) subtypes. We tested the three recurrent protein-truncating variants FANCM :p.Arg658*, p.Gln1701*, and p.Arg1931* for association with breast cancer risk in 67,112 cases, 53,766 controls, and 26,662 carriers of pathogenic variants of BRCA1 or BRCA2. These three variants were also studied functionally by measuring survival and chromosome fragility in FANCM -/- patient-derived immortalized fibroblasts treated with diepoxybutane or olaparib. We observed that FANCM :p.Arg658* was associated with increased risk of ER-negative disease and TNBC (OR = 2.44, P = 0.034 and OR = 3.79; P = 0.009, respectively). In a country-restricted analysis, we confirmed the associations detected for FANCM :p.Arg658* and found that also FANCM :p.Arg1931* was associated with ER-negative breast cancer risk (OR = 1.96; P = 0.006). The functional results indicated that all three variants were deleterious affecting cell survival and chromosome stability with FANCM :p.Arg658* causing more severe phenotypes. In conclusion, we confirmed that the two rare FANCM deleterious variants p.Arg658* and p.Arg1931* are risk factors for ER-negative and TNBC subtypes. Overall our data suggest that the effect of truncating variants on breast cancer risk may depend on their position in the gene. Cell sensitivity to olaparib exposure, identifies a possible therapeutic option to treat FANCM -associated tumors.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

CRISPR Screens in Synthetic Lethality and Combinatorial Therapies for Cancer

  • Castells Roca, Laia|||0000-0002-4604-9999
  • Tejero Laguna, Eudald|||0000-0002-7536-4322
  • Rodriguez Santiago, Benjamin|||0000-0003-1167-3852
  • Surralles, Jordi|||0000-0002-4041-7519
Cancer is a complex disease resulting from the accumulation of genetic dysfunctions. Tumor heterogeneity causes the molecular variety that divergently controls responses to chemotherapy, leading to the recurrent problem of cancer reappearance. For many decades, efforts have focused on identifying essential tumoral genes and cancer driver mutations. More recently, prompted by the clinical success of the synthetic lethality (SL)-based therapy of the PARP inhibitors in homologous recombinant deficient tumors, scientists have centered their novel research on SL interactions (SLI). The state of the art to find new genetic interactions are currently large-scale forward genetic CRISPR screens. CRISPR technology has rapidly evolved to be a common tool in the vast majority of laboratories, as tools to implement CRISPR screen protocols are available to all researchers. Taking advantage of SLI, combinatorial therapies have become the ultimate model to treat cancer with lower toxicity, and therefore better efficiency. This review explores the CRISPR screen methodology, integrates the up-to-date published findings on CRISPR screens in the cancer field and proposes future directions to uncover cancer regulation and individual responses to chemotherapy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Improved collection of hematopoietic stem cells and progenitors from Fanconi anemia patients for gene therapy purposes

  • Sevilla, Julián|||0000-0002-6852-1860
  • Navarro Ordóñez, Susana|||0000-0002-0764-5384
  • Río, Paula
  • Sánchez Domínguez, Rebeca
  • Zubicaray, Josune|||0000-0003-4115-9598
  • Gálvez, Eva
  • Merino, Eva
  • Sebastián, Elena
  • Azqueta, Carmen
  • Casado, José A.|||0000-0003-2479-1508
  • Segovia, Jose C.|||0000-0003-4101-6124
  • Alberquilla, Omaira|||0000-0002-0301-8340
  • Bogliolo, Massimo|||0000-0001-8240-7784
  • Román-Rodríguez, Francisco J.
  • Giménez, Yari|||0000-0002-8936-0007
  • Larcher, Lise
  • Salgado Sánchez, Rocío Nieves|||0000-0003-1678-8982
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Hladun, Raquel|||0000-0002-3191-1750
  • Castillo, Ana
  • Soulier, Jean|||0000-0002-8734-5356
  • Querol, Sergi|||0000-0002-1105-8633
  • Fernández, Jesús
  • Schwartz, Jonathan|||0000-0002-2211-4151
  • García de Andoín, Nagore|||0000-0003-2660-2600
  • López, Ricardo
  • Català, Albert|||0000-0003-0133-1752
  • Surralles, Jordi|||0000-0002-4041-7519
  • Díaz de Heredia, Cristina|||0000-0001-8086-296X
  • Bueren, Juan|||0000-0002-3228-7013
Difficulties in the collection of hematopoietic stem and progenitor cells (HSPCs) from Fanconi anemia (FA) patients have limited the gene therapy in this disease. We have investigated (, NCT02931071) the safety and efficacy of filgrastim and plerixafor for mobilization of HSPCs and collection by leukapheresis in FA patients. Nine of eleven enrolled patients mobilized beyond the threshold level of 5 CD34 + cells/μL required to initiate apheresis. A median of 21.8 CD34 + cells/μL was reached at the peak of mobilization. Significantly, the oldest patients (15 and 16 years old) were the only ones who did not reach that threshold. A median of 4.27 million CD34 + cells/kg was collected in 2 or 3 aphereses. These numbers were markedly decreased to 1.1 million CD34 + cells/kg after immunoselection, probably because of weak expression of the CD34 antigen. However, these numbers were sufficient to facilitate the engraftment of corrected HSPCs in non-conditioned patients. No procedure-associated serious adverse events were observed. Mobilization of CD34 + cells correlated with younger age, higher leukocyte counts and hemoglobin values, lower mean corpuscular volume, and higher proportion of CD34 + cells in bone marrow (BM). All these values offer crucial information for the enrollment of FA patients for gene therapy protocols. Mobilization and collection of HSPCs from FA patients with sufficient HSPC reserve is a safe and efficient procedure, incorporating filgrastim and plerixafor as mobilization agents. Adequate HSPC mobilization correlates with younger age, higher leukocyte counts and hemoglobin values, lower mean corpuscular volume, and higher BM CD34 + cell numbers.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

CDK5RAP3, a New BRCA2 Partner That Regulates DNA Repair, Is Associated with Breast Cancer Survival

  • Minguillón Pedreño, Jordi|||0000-0003-2124-8294
  • Ramírez de Haro, Ma. José|||0000-0003-1417-7731
  • Rovirosa Mulet, Llorenç|||0000-0003-2986-9001
  • Bustamante-Madrid, Pilar|||0000-0003-4540-9742
  • Camps-Fajol, Cristina
  • Ruiz de Garibay, Gorka|||0000-0001-9936-8419
  • Shimelis, Hermela
  • Montanuy Escribano, Helena
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Hernández Viedma, Gonzalo|||0000-0002-3048-9607
  • Bogliolo, Massimo|||0000-0001-8240-7784
  • Castillo, Pau
  • Soucy, Penny
  • Martrat, Griselda
  • Gómez Moruno, Antonio|||0000-0001-5308-981X
  • Cuadras, Daniel|||0000-0001-8780-1764
  • García, María J.
  • Gayarre, Javier|||0000-0003-0377-6712
  • Lázaro García, Conxi|||0000-0002-7198-5906
  • Benitez, Javier|||0000-0002-0923-7202
  • Couch, Fergus J.
  • Pujana, Miguel Angel|||0000-0003-3222-4044
  • Surralles, Jordi|||0000-0002-4041-7519
BRCA2 is essential for homologous recombination DNA repair. BRCA2 mutations lead to genome instability and increased risk of breast and ovarian cancer. Similarly, mutations in BRCA2-interacting proteins are also known to modulate sensitivity to DNA damage agents and are established cancer risk factors. Here we identify the tumor suppressor CDK5RAP3 as a novel BRCA2 helical domain-interacting protein. CDK5RAP3 depletion induced DNA damage resistance, homologous recombination and single-strand annealing upregulation, and reduced spontaneous and DNA damage-induced genomic instability, suggesting that CDK5RAP3 negatively regulates double-strand break repair in the S-phase. Consistent with this cellular phenotype, analysis of transcriptomic data revealed an association between low CDK5RAP3 tumor expression and poor survival of breast cancer patients. Finally, we identified common genetic variations in the CDK5RAP3 locus as potentially associated with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Our results uncover CDK5RAP3 as a critical player in DNA repair and breast cancer outcomes.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Clinical consequences of BRCA2 hypomorphism

  • Castells Roca, Laia|||0000-0002-4604-9999
  • Gutiérrez-Enríquez, Sara|||0000-0002-1711-6101
  • Bonache, Sandra|||0000-0002-7395-8143
  • Bogliolo, Massimo|||0000-0001-8240-7784
  • Carrasco, Estela|||0000-0003-1964-7675
  • Aza-Carmona, Miriam|||0000-0003-4448-9541
  • Montalban, Gemma|||0000-0002-6958-4759
  • Muñoz-Subirana, N.
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Cruz Zambrano, Cristina|||0000-0002-6474-7504
  • Llop Guevara, Alba|||0000-0002-7913-9472
  • Ramírez de Haro, Ma. José|||0000-0003-1417-7731
  • Saura Manich, Cristina|||0000-0001-8296-5065
  • Lasa, Adriana|||0000-0001-9957-9646
  • Serra, Violeta|||0000-0001-6620-1065
  • Diez, Orland|||0000-0001-7339-0570
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Surralles, Jordi|||0000-0002-4041-7519
The tumor suppressor FANCD1/BRCA2 is crucial for DNA homologous recombination repair (HRR). BRCA2 biallelic pathogenic variants result in a severe form of Fanconi anemia (FA) syndrome, whereas monoallelic pathogenic variants cause mainly hereditary breast and ovarian cancer predisposition. For decades, the co-occurrence in trans with a clearly pathogenic variant led to assume that the other allele was benign. However, here we show a patient with biallelic BRCA2 (c.1813dup and c.7796 A.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

  • Figlioli, Gisella
  • Catucci, Irene
  • Caleca, Laura
  • Lasheras, Sandra Viz
  • Pujol, Roser
  • Balmaña Gelpí, Judith
  • Diez Gibert, Orland
  • Bogliolo, Massimo
Càncer de mama; Genètica del càncer, Cáncer de mama; Genética del cáncer, Breast cancer; Cancer genetics, Breast cancer is a common disease partially caused by genetic risk factors. Germline pathogenic variants in DNA repair genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 are associated with breast cancer risk. FANCM, which encodes for a DNA translocase, has been proposed as a breast cancer predisposition gene, with greater effects for the ER-negative and triple-negative breast cancer (TNBC) subtypes. We tested the three recurrent protein-truncating variants FANCM:p.Arg658*, p.Gln1701*, and p.Arg1931* for association with breast cancer risk in 67,112 cases, 53,766 controls, and 26,662 carriers of pathogenic variants of BRCA1 or BRCA2. These three variants were also studied functionally by measuring survival and chromosome fragility in FANCM -/- patient-derived immortalized fibroblasts treated with diepoxybutane or olaparib. We observed that FANCM:p.Arg658* was associated with increased risk of ER-negative disease and TNBC (OR = 2.44, P = 0.034 and OR = 3.79; P = 0.009, respectively). In a country-restricted analysis, we confirmed the associations detected for FANCM:p.Arg658* and found that also FANCM:p.Arg1931* was associated with ER-negative breast cancer risk (OR = 1.96; P = 0.006). The functional results indicated that all three variants were deleterious affecting cell survival and chromosome stability with FANCM:p.Arg658* causing more severe phenotypes. In conclusion, we confirmed that the two rare FANCM deleterious variants p.Arg658* and p.Arg1931* are risk factors for ER-negative and TNBC subtypes. Overall our data suggest that the effect of truncating variants on breast cancer risk may depend on their position in the gene. Cell sensitivity to olaparib exposure, identifies a possible therapeutic option to treat FANCM-associated tumors., Peterlongo laboratory is supported by Associazione Italiana Ricerca sul Cancro (AIRC; IG2015 no.16732) to P. Peterlongo and by a fellowship from Fondazione Umberto Veronesi to G. Figlioli. Surrallés laboratory is supported by the ICREA-Academia program, the Spanish Ministry of Health (projects FANCOSTEM and FANCOLEN), the Spanish Ministry of Economy and Competiveness (projects CB06/07/0023 and RTI2018-098419-B-I00), the European Commission (EUROFANCOLEN project HEALTH-F5-2012-305421 and P-SPHERE COFUND project), the Fanconi Anemia Research Fund Inc, and the “Fondo Europeo de Desarrollo Regional, una manera de hacer Europa” (FEDER). CIBERER is an initiative of the Instituto de Salud Carlos III, Spain.